ELUTIA INC.
ELUTNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $12.3M | $24.4M | $24.7M | $23.8M | $47.4M | $42.7M |
| Operating income | −$26.9M | −$35.7M | −$30.5M | −$35.2M | −$23.0M | −$13.6M |
| Net income | $53.4M | −$53.9M | −$37.7M | −$32.9M | −$24.8M | −$21.8M |
| Total assets | $62.4M | $36.1M | $43.4M | $68.8M | $67.2M | $82.8M |
| Total liabilities | $34.7M | $82.4M | $82.0M | $73.9M | $53.6M | $62.0M |
| Equity | $27.7M | −$46.3M | −$38.6M | −$5.0M | $13.5M | $20.8M |
| EPS (diluted) | $0.87 | $-1.86 | $-2.07 | $-2.38 | $-2.38 | $-8.88 |
| Shares out. | 45.9M | 29.1M | 18.2M | 13.8M | 10.4M | 2.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −218.9%
- Net margin
- 434.2%
- Return on equity
- 192.9%
- Return on assets
- 85.6%
- Return on capital (ROCE)
- −72.3%
- Liabilities / assets
- 55.6%
- Debt / equity
- 1.25×
- Book value / share
- $0.60
- Revenue growth (YoY)
- −49.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -8.05distress
- Accruals / assets
- 157.5%high accruals
- Beneish M-Score
- 4.73elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Beneish M-Score elevated — earnings-manipulation screen flag
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Alyeska Investment Group, L.P.Passive (13G)Feb 17, 2026
- Knollwood Investment Advisory, LlcPassive (13G)Feb 13, 2026
- Nantahala Capital Management, LlcPassive (13G)Feb 13, 2026
- Hirschman OrinPassive (13G)Jan 28, 2026
- Rakin KevinActivist (13D)Dec 15, 2025
- Highcape Capital, L.P.Activist (13D)Mar 13, 2025
- Silverarc Capital Management, LlcPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Neels Guido JDirector | Dec 10, 2025 | Option exercise | 6,250 | — |
| Williams Michelle LerouxOfficer — CHIEF SCIENTIFIC OFFICER | Mar 10, 2026 | Option exercise | 12,500 | — |
| Mills C RandalOfficer — PRESIDENT AND CEO | Mar 10, 2026 | Option exercise | 27,084 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 141,552 | 1.0 | +12.2% |
| Apr 30, 2026 | 126,205 | 2.3 | +0.9% |
| Apr 15, 2026 | 125,015 | 1.7 | -2.8% |
| Mar 31, 2026 | 128,627 | 1.0 | +27.6% |
| Mar 13, 2026 | 100,767 | 1.0 | -31.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Results of operationsMar 11, 2026
- Director / officer changeMar 9, 2026
- Other material eventMar 4, 2026
- Results of operationsJan 12, 2026
- Delisting / listing-standard noticeJan 2, 2026
- Delisting / listing-standard noticeNov 12, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.